| Walter J. Koroshetz | |
|---|---|
| Photo placeholder | |
| Affiliations | NIH NINDS |
| Country | USA |
| H-index | 100 |
| Research Focus | Alzheimer's Disease, Parkinson's Disease |
| Mechanisms | Clinical care, Research funding |
Walter J. Koroshetz is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Koroshetz has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at NIH and NINDS, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Their program contributes to translational and mechanistic work in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--.
The lab emphasizes Clinical care to connect molecular findings with patient outcomes. The lab emphasizes Research funding to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Koroshetz's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Akil H et al.. "Neuroscience Training for the 21st Century." [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (2016). [DOI)(https://doi.org/10.1016/j.neuron.2016.05.030)
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). [DOI)(https://doi.org/10.1016/j.jalz.2014.10.008)
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). [DOI)(https://doi.org/10.1007/s10571-016-0334-7)
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI)
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI)
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI)
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI)
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI)
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI: 10.1016/j.neuron.2016.05.030) PubMed: 27253446
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI: 10.1016/j.jalz.2014.10.008) PubMed: 25510382
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI: 10.1007/s10571-016-0334-7) PubMed: 27095366
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI: 10.1289/ehp.11702) PubMed: 19165397
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI: 10.1016/j.jalz.2007.06.001) PubMed: 18631953
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI: 10.1212/wnl.55.6.800) PubMed: 10993999
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI: 10.1002/ana.24261) PubMed: 25164235
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI: 10.1212/wnl.44.8.1369) PubMed: 7914682
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI)
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI)
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI)
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI)
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI)
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI)
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI)
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI)
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI: 10.1016/j.neuron.2016.05.030) PubMed: 27253446
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI: 10.1016/j.jalz.2014.10.008) PubMed: 25510382
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI: 10.1007/s10571-016-0334-7) PubMed: 27095366
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI: 10.1289/ehp.11702) PubMed: 19165397
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI: 10.1016/j.jalz.2007.06.001) PubMed: 18631953
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI: 10.1212/wnl.55.6.800) PubMed: 10993999
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI: 10.1002/ana.24261) PubMed: 25164235
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI: 10.1212/wnl.44.8.1369) PubMed: 7914682
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI)
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI)
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI)
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI)
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI)
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI)
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI)
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI)
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI: 10.1016/j.neuron.2016.05.030) PubMed: 27253446
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI: 10.1016/j.jalz.2014.10.008) PubMed: 25510382
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI: 10.1007/s10571-016-0334-7) PubMed: 27095366
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI: 10.1289/ehp.11702) PubMed: 19165397
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI: 10.1016/j.jalz.2007.06.001) PubMed: 18631953
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI: 10.1212/wnl.55.6.800) PubMed: 10993999
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI: 10.1002/ana.24261) PubMed: 25164235
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI: 10.1212/wnl.44.8.1369) PubMed: 7914682
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI)
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI)
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI)
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI)
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI)
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI)
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI)
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI)
[Akil H et al.. "Neuroscience Training for the 21st Century." Neuron (2016). DOI: 10.1016/j.neuron.2016.05.030) PubMed: 27253446
[Snyder HM et al.. "Vascular contributions to cognitive impairment and dementia including Alzheimer's Disease." Alzheimers Dement (2015). DOI: 10.1016/j.jalz.2014.10.008) PubMed: 25510382
[Corriveau RA et al.. "The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline." Cellular and molecular neurobiology (2016). DOI: 10.1007/s10571-016-0334-7) PubMed: 27095366
[Bronstein J et al.. "Meeting report: consensus statement-Parkinson's Disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007." Environmental health perspectives (2009). DOI: 10.1289/ehp.11702) PubMed: 19165397
[Trojanowski JQ et al.. "New directions for Frontotemporal Dementia drug discovery." Alzheimers Dement (2008). DOI: 10.1016/j.jalz.2007.06.001) PubMed: 18631953
[Gwinn-Hardy K et al.. "Spinocerebellar Ataxia type 2 with parkinsonism in ethnic Chinese." Neurology (2000). DOI: 10.1212/wnl.55.6.800) PubMed: 10993999
[Sieber BA et al.. "Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference." Annals of neurology (2014). DOI: 10.1002/ana.24261) PubMed: 25164235
[Hersch S et al.. "The neurogenetics genie: testing for the Huntington's Disease mutation." Neurology (1994). DOI: 10.1212/wnl.44.8.1369) PubMed: 7914682
Recent publications by [Walter J. Koroshetz[/researchers/[john-koroshetz[/researchers/[john-koroshetz[/researchers/[john-koroshetz--TEMP--/researchers)--FIX-- focus on NINDS research initiatives, neurodegenerative disease programs, and translational neurology.
The study of Walter J. Koroshetz has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.